Dr. Federico Cappuzzo MD

Professor & Director of Medical Oncology , Ospedali Riuniti Livorno

What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

GLG News by Dr. Federico Cappuzzo MD, Professor & Director of Medical Oncology

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Should we use cetuximab in all NSCLC patients?

June 2, 2008

Erbitux Slightly Boosts Survival in Cancer Study | online.wsj.com

  The FLEX trial, a randomized phase 3 study comparing cisplatin-vinorelbine versus the same regimen plus cetuximab, recently showed that the addition of the monoclonal antibody to chemotherapy significantly prolong survival in chemonaive NSCLC. Several aspects could limit the wide use of cetuximab.

Page : 11 to 1 of 1

Subscribe to Updates

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines

Leading institutions connect with Federico Cappuzzo through GLG

Most Popular Healthcare News